>
Switch to:

Myovant Sciences Change In Inventory

: $-5.0 Mil (TTM As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Myovant Sciences's change in inventory for the quarter that ended in Mar. 2022 was $-0.8 Mil. It means Myovant Sciences's inventory increased by $0.8 Mil from Dec. 2021 to Mar. 2022 .

Myovant Sciences's change in inventory for the fiscal year that ended in Mar. 2022 was $-5.0 Mil. It means Myovant Sciences's inventory increased by $5.0 Mil from Mar. 2021 to Mar. 2022 .

Myovant Sciences's Total Inventories for the quarter that ended in Mar. 2022 was $7.6 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Myovant Sciences's Days Inventory for the quarter that ended in Mar. 2022 was 36.83.

Total Inventories can be measured by Days Sales of Inventory (DSI). Myovant Sciences's days sales of inventory (DSI) for the quarter that ended in Mar. 2022 was 11.35.

Inventory Turnover measures how fast the company turns over its inventory within a year. Myovant Sciences's Inventory Turnover for the quarter that ended in Mar. 2022 was 2.48.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.12.


Myovant Sciences Change In Inventory Historical Data

The historical data trend for Myovant Sciences's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Change In Inventory
Premium Member Only Premium Member Only - - - -2.61 -4.97

Myovant Sciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Change In Inventory Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.56 -1.97 -0.60 -0.85

Myovant Sciences Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Myovant Sciences's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Total Inventories/Cost of Goods Sold*Days in Period
=7.1605/17.742*365 / 4
=36.83

2. Total Inventories can be measured by Days Sales of Inventory (DSI).

Myovant Sciences's Days Sales of Inventory for the quarter that ended in Mar. 2022 is calculated as

Days Sales of Inventory (DSI)=Total Inventories/Revenue*Days in Period
=7.1605/57.567*365 / 4
=11.35

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Myovant Sciences's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Myovant Sciences's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences Change In Inventory Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)